Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | Phase 3 | terminated | Apr 8, 2014 | Abnoba Gmbh | The study was terminated because the required number of patients cannot be reached in the… | Safety / toxicity |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder…(GCISAVE) | Phase 2 | terminated | Oct 27, 2017 | University Hospital, Bordeaux | ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in recruitment,… | Enrollment / accrual |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed… | Phase 3 | withdrawn | Apr 27, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients… | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Corcept Therapeutics | The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the… | Enrollment / accrual |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Jan 20, 2021 | Thomas Hope | Low accrual | Enrollment / accrual |
| NCT04030559 | Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer… | Phase 2 | terminated | Jul 24, 2019 | University of California, Davis | PI choice; poor accrual | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory… | Early Phase 1 | withdrawn | Nov 29, 2024 | Kousai Bio Co., Ltd. | Due to a strategic adjustment, the company has decided to terminate the project. | Sponsor / business decision |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone… | Phase 2 | withdrawn | Jun 17, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05362032 | Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted… | N/A | suspended | May 5, 2022 | OHSU Knight Cancer Institute | Study team paused enrollment | Enrollment / accrual |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT06456411 | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain… | N/A | terminated | Jun 13, 2024 | Roswell Park Cancer Institute | PI left | Investigator |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | Early Phase 1 | withdrawn | Jul 7, 2025 | Thomas Hope | Sponsor funding | Funding |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial… | Phase 2 | terminated | Oct 14, 2022 | University of Washington | Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the… | Enrollment / accrual |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Phase 2 | terminated | Oct 20, 2022 | Partner Therapeutics, Inc. | Merus terminated the study early due to changes in organizational priorities. | Other (stated, no rule matched) |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | Phase 1 / Phase 2 | withdrawn | Aug 28, 2025 | Centre Leon Berard | Molecule not available from the laboratory | Other (stated, no rule matched) |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant,… | Phase 1 / Phase 2 | terminated | Sep 21, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib… | Other (stated, no rule matched) |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for…(ARTIA-Bladder) | N/A | terminated | Jan 26, 2023 | Varian, a Siemens Healthineers Company | Low enrollment | Enrollment / accrual |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT03575611 | Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell… | Phase 2 | suspended | Jul 2, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant…(DICE) | Phase 2 | terminated | Mar 11, 2019 | Cancer Trials Ireland | Insufficient accrual | Enrollment / accrual |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | Phase 1 | terminated | Apr 21, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable… | Phase 2 | terminated | Sep 8, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal… | Phase 2 | terminated | May 27, 2021 | M.D. Anderson Cancer Center | Withdrawal of funding from the supporter (Mirati Therapeutics) | Funding |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone…(CONTACT-03) | Phase 3 | terminated | Apr 8, 2020 | Hoffmann-La Roche | As the study did not meet it's primary endpoint a decision was made to terminate the study. | Other (stated, no rule matched) |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic… | Phase 2 | terminated | Dec 4, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | N/A | withdrawn | Dec 16, 2025 | The Royal Wolverhampton Hospitals NHS Trust | Study no longer going ahead | Other (stated, no rule matched) |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With…(CELLO-1) | Phase 1 / Phase 2 | terminated | Nov 27, 2019 | Epizyme, Inc. | The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in… | Safety / toxicity |
| NCT06860386 | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | Phase 2 | suspended | Mar 6, 2025 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT06114940 | Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma…(PLUTO) | Phase 2 | terminated | Nov 2, 2023 | Jinling Hospital, China | Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for… | Other (stated, no rule matched) |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment | Enrollment / accrual |
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in… | Phase 1 | terminated | May 20, 2021 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | Phase 2 | terminated | Jan 9, 2023 | Thomas Jefferson University | Loss of required MRI resources needed to conduct protocol-specified procedures | Other (stated, no rule matched) |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With… | Phase 1 | terminated | Apr 20, 2016 | Regeneron Pharmaceuticals | Due to a Dose Limiting Toxicity. | Safety / toxicity |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in… | Phase 2 | terminated | May 24, 2017 | National Cancer Institute (NCI) | Study closed to enrollment due to low accrual. | Enrollment / accrual |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial(ARCITECT) | Phase 2 | suspended | Jul 3, 2023 | Michael B. Atkins, MD | Interim Analysis | Efficacy / futility |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With…(TEM-GU) | Phase 1 / Phase 2 | terminated | Dec 4, 2024 | Genenta Science | Persistent challenges have been encountered in patient recruitment, difficulty in identifying a… | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 26, 2026source: clinicaltrials